Seroatlas · Human Serome Atlas

FXYD3

FXYD domain-containing ion transport regulator 3

Also known as: FXYD3_HUMAN, MAT-8, PLML

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q14802
Gene: FXYD3
Ensembl: ENSG00000089356
Chromosome: 19
Canonical length: 87 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins, Transporters
Subcellular location: Nucleoplasm,Plasma membrane
Secretome location: Intracellular and membrane

OverviewNCBI Gene

This gene belongs to a small family of FXYD-domain containing regulators of Na+/K+ ATPases which share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD, and containing 7 invariant and 6 highly conserved amino acids. This gene encodes a cell membrane protein that may regulate the function of ion-pumps and ion-channels. This gene may also play a role in tumor progression. Alternative splicing results in multiple transcript variants encoding distinct isoforms.[provided by RefSeq, Oct 2008]

Canonical amino-acid sequenceUniProt

87 residues, UniProt reviewed canonical sequence.

>Q14802|FXYD3
     1  MQKVTLGLLV FLAGFPVLDA NDLEDKNSPF YYDWHSLQVG GLICAGVLCA MGIIIVMSAK
    61  CKCKFGQKSG HHPGETPPLI TPGSAQS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FXYD3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.56
Highest tissue expression: 1,697 nTPM

Expression across tissuesHPA

Tissue

rectum: 1,697 nTPM
colon: 1,382 nTPM
esophagus: 671 nTPM
salivary gland: 575 nTPM
skin: 553 nTPM
stomach: 544 nTPM

Single-cell type

colonocytes: 108 nCPM
papillary tip epithelial cells: 81 nCPM
enterocytes: 31 nCPM
goblet cells: 27 nCPM
enteric transient amplifying cells: 19 nCPM
foveolar cells: 18 nCPM

Immune cell

plasmacytoid DC: 0.7 nTPM
neutrophil: 0.1 nTPM
total PBMC: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM

Brain region

medulla oblongata: 8.7 nTPM
choroid plexus: 7.7 nTPM
cerebral cortex: 7.5 nTPM
basal ganglia: 7.4 nTPM
midbrain: 7.4 nTPM
amygdala: 7.3 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.31
gnomAD pLI: 0
gnomAD missense Z: 0.09
DepMap mean gene effect: -0.05
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of FXYD3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

ATP1A2-ATP1B1

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FXYD3 as an antibody target. Whether an autoantibody or antibody against FXYD3 could matter depends on whether native FXYD3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FXYD3 is annotated at the cell surface, where native FXYD3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label FXYD3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...